Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.
about
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyChemotherapy and its evolving role in the management of advanced prostate cancerSequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapyPhase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinHigh-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.The STAMPEDE trial: paradigm-changing data through innovative trial design.SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.Metastatic castration-resistant prostate cancer: time for innovation.Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.Therapeutic vaccines for prostate cancer: recent advances and future directions.Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer.Sipuleucel-T and immunotherapy in the treatment of prostate cancer.Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
P2860
Q26825053-B742309F-D637-4124-A852-48E16A44CEEBQ27008883-ABD2DC24-4482-4D93-A5F1-36052135BCFEQ27022715-CC2B9EAE-E6B3-4D57-B618-E81CCDAAB7BDQ33429309-F315B9F5-0D6E-45AF-AF84-82744318EF12Q35979551-D3DA020B-0B4B-4FA6-AC4C-605EBB546427Q36152474-3554EB1C-3792-4A95-B978-4AA63B1FFB43Q36163344-53523CE8-CC55-409B-A33B-98A25AE267D7Q36688923-CFFF9D98-343B-48AD-BCA6-0C02A57F58FAQ37235511-1859529A-E7C3-4806-BA60-2BA38E25DB82Q38190112-2C9FF71C-7DC2-420D-A369-9345EACEBC89Q38312041-87D1D2CE-88D5-4BC6-BBBF-D4E8196158B1Q38541877-F3784DFD-AE23-456A-95E9-34349F78B6A3Q38575004-63C18668-7C31-4C09-BE6F-95C86D5838AEQ38612982-A6EF5230-C50B-414D-8C23-8542A35748FBQ38906558-10D61C26-1765-4984-8397-DAF9D273B478Q39037597-E26F8B88-8371-412C-AE96-E108691510E7Q39257661-93494039-2E5F-430B-BE1F-9432CE68BAA2Q47126582-36B41102-0954-42DF-8794-8DE7AFD24B22Q49578235-A3CC785B-C957-413F-8162-F4BF32E91825Q50883487-05B6B640-E6D1-472E-932D-7A6F246CFCAEQ53062915-F1414FDF-D61F-497F-992D-D80DBD0EAA7BQ53786874-CA6BA106-145C-4386-8FA4-A09061D9E425
P2860
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Phase III trials with docetaxe ...... o learn from past experiences.
@en
Phase III trials with docetaxe ...... o learn from past experiences.
@nl
type
label
Phase III trials with docetaxe ...... o learn from past experiences.
@en
Phase III trials with docetaxe ...... o learn from past experiences.
@nl
prefLabel
Phase III trials with docetaxe ...... o learn from past experiences.
@en
Phase III trials with docetaxe ...... o learn from past experiences.
@nl
P2860
P356
P1476
Phase III trials with docetaxe ...... to learn from past experiences
@en
P2093
Mario A Eisenberger
P2860
P304
P356
10.1200/JCO.2013.48.8825
P407
P577
2013-04-08T00:00:00Z